[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 1284 Introduced in House (IH)]

<DOC>






117th CONGRESS
  2d Session
H. RES. 1284

  Of inquiry directing the Secretary of Health and Human Services to 
provide certain documentation to the House of Representatives relating 
to the negotiation of prices for prescription drugs under the Medicare 
                       prescription drug program.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             July 26, 2022

 Mrs. Rodgers of Washington submitted the following resolution; which 
          was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                               RESOLUTION


 
  Of inquiry directing the Secretary of Health and Human Services to 
provide certain documentation to the House of Representatives relating 
to the negotiation of prices for prescription drugs under the Medicare 
                       prescription drug program.

    Resolved, That the Secretary of Health and Human Services (referred 
to herein as the ``Secretary'') is directed to furnish to the House of 
Representatives, not later than 14 days after adoption of this 
resolution, copies of any document, record, audio recording, 
memorandum, call log, correspondence (electronic or otherwise), or 
other communication in the Secretary's possession, or any portion of 
any document, record, audio recording, memorandum, call log, 
correspondence (electronic or otherwise), or other communication in the 
Secretary's possession, that refers or relates to any of the following:
            (1) Communications by staff of the White House with any 
        group or expert that is not staff of the White House regarding 
        the implications of imposing a 95 percent excise tax on drug 
        manufacturers that fail to comply with price setting 
        negotiations with the Secretary under the Medicare prescription 
        drug program under part D of title XVIII of the Social Security 
        Act and the potential loss of the development of future drugs 
        and cures.
            (2) Internal communications among staff of the White House 
        regarding the implications described in paragraph (1) and the 
        potential loss of development described in such paragraph.
            (3) Communications by staff of the White House with any 
        group or expert that is not staff of the White House regarding 
        the implications of establishing inflation penalties under the 
        Medicare prescription drug program under such part D on launch 
        prices for future prescription drugs.
            (4) Internal communications among staff of the White House 
        regarding the implications described in paragraph (3).
                                 <all>